Archive for the ‘Member Press Releases’ Category

Apexian Pharmaceuticals’ Dr. Mark Kelley recognized as an outstanding researcher at Indiana University/Purdue University IUPUI

April 26, 2018

Apexian Logo Font

Indianapolis, IN – Apexian Pharmaceuticals, a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs, is pleased to announce that its Chief Scientific Officer, Mark Kelley, PhD, was recognized as an outstanding scholar and researcher during the annual IUPUI Chancellor’s Academic Honors Convocation on April 20. Dr. Kelley was named the recipient of the Glenn W. Irwin Jr., M.D. Research Scholar Award for his high level of achievement in research, scholarship, or creative activity that stands as a visible representative of excellence for the entire campus.  The award recognizes the outstanding achievements of Dr. Glenn W. Irwin Jr., who was a professor, dean of IU School of Medicine, chancellor of the Indianapolis campus and vice president of IU.

The convocation, hosted by IUPUI Chancellor Nasser H. Paydar, celebrated excellence across all areas of IUPUI’s mission: teaching and learning; research, scholarship and creative activity; civic engagement; and diversity.

Steve Carchedi, Apexian’s CEO, said, “Dr. Kelley is a dedicated researcher whose work is making a significant impact in the lives of patients. This is a well-deserved recognition and we are honored that he is leading the way for Apexian.”

Dr. Kelley’s work has focused on translational research in DNA damage and repair to determine how those activities can be exploited therapeutically to treat cancers and protect normal cells from DNA damage. He has focused specifically on the enzyme called APE1 as a therapeutic target in cancers and other diseases. Dr. Kelley discovered and has been developing a specific inhibitor of APE1, called APX3330, which is now being studied in a Phase I clinical trial. The drug has potential uses in a number of cancers including ovarian, colon, bladder, pancreatic, leukemia, and other adult and pediatric cancers.

Dr. Kelley is the Betty and Earl Herr Professor of Pediatric Oncology Research and professor of pediatrics and of biochemistry and molecular biology at IU School of Medicine and associate director of basic science research at the Indiana University Melvin and Bren Simon Cancer Center.

About Apexian Pharmaceuticals
Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs.  Apexian’s lead drug candidate is named APX3330. To learn more about Apexian Pharmaceuticals, please visit the company’s website at www.ApexianPharma.com

Media Contact: Roger D. Miller
Email: PR@Apexianpharma.com
Telephone:  844-463-3330 x113

 

Advertisements

BASi and Phlebotics Form Strategic Alliance; Continuing a Commitment to Automated Blood Sampling

April 4, 2018

WEST LAFAYETTE, Ind., April 4, 2018 (Newswire.com) –  Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced a technology alliance with Phlebotics, Inc. This agreement is the latest of BASi partnerships, including those with Joanneum Research and PalmSens, to expand  their offering of products and services that improve data and increase the speed of bringing new drugs to market.

This alliance focuses on technology for automated blood sampling. For nearly 20 years, the BASi Culex® Automated Blood Sampling System has been a game changer in drug research by enabling stress-free sampling from large and small animal models. Phlebotics will continue its developments toward clinical applications.

BASi and Phlebotics have previously partnered on related projects. This new alliance will support Phlebotics through research and beta testing stages of product development. “When you consider BASi can sample blood from freely moving rodents with reduced pain, stress, blood loss, and labor, it makes sense to consider the advantages for clinical trial subjects and patients,” said Pete Kissinger, a founder of both firms. “This partnering strategy will give us a head start in getting the product into the hands of clinicians.”

Philip Downing, BASi Senior Vice President of Preclinical Services, added, “BASi is excited to collaborate with a partner who is equally committed to advancing automated pharmacology practices. At the animal level, we have seen an impact on the speed and quality of data that can be achieved with automation. We’re excited to see this technology being explored for clinical applications, and we expect to advance our research for animal products, as well.”

For BASi, this alliance supports the expansion of the company’s preclinical product and service offerings. For Phlebotics, the alliance will facilitate using the knowledge gained from its initial clinical trials to refine their product for future hospital workflows. Pete Kissinger added, “We see the Phlebot as a component in the Internet of Medical Things (IoMT), or what is sometimes called the smart ICU.”

 

About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing Preclinical, Toxicological and Bioanalytical contract research services and monitoring instruments to the world’s leading drug development companies and medical research organizations. The Company’s in vivo automated sampling center is a purpose-built facility including ten in vivo labs, colony rooms for rats and mice with individually ventilated housing systems (IVCs), rodent surgical site, and a wet lab and cage wash facility that is complemented by state-of-the-art cold storage, formulations and bioanalytical facilities. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit http://www.BASinc.com for more information about BASi.

About Phlebotics, Inc.
Phlebotics, Inc. is a development stage company organized in 2007 expressly for the purpose of improving medical diagnostics in hospitalized patients as well as early-stage clinical trials for novel drugs and formulations using automated serial blood sampling that reduces risk, discomfort, blood waste and labor while improving data quality. Phlebotics products are for investigational use only (IUO) and are not approved by the Food and Drug Administration for the prevention, diagnosis or treatment of disease. Visit http://www.phlebot.com to learn more.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.

Company Contact:
Jill Blumhoff
Chief Financial Officer &
Vice President of Finance
Phone: 765.497.8381
jblumhoff@BASinc.com

B2S Life Sciences Plans Long-Term Growth, R&D in Central Indiana

March 7, 2018

FRANKLIN, Ind. (March 7, 2018) – B2S Life Sciences, a biotherapeutic drug development company, announced plans today to expand its operations in Johnson County, creating up to 23 new, high-wage jobs by 2020.

“Indiana has earned a reputation as a global leader in life sciences, ranking second in the nation for worldwide exports,” said Elaine Bedel, president of the Indiana Economic Development Corporation (IEDC). “At its new facility, B2S can continue to advance new technologies and life-saving research, while simultaneously investing in Indiana’s future workforce, propelling other entrepreneurs and creating good jobs for Hoosiers. We’re excited to witness B2S’ continued growth alongside our life sciences sector here in Indiana.”

The company, which develops pharmaceutical and diagnostic biological reagents, is investing $1.5 million to expand and renovate its nearly 3,000-square foot facility at 97 E. Monroe St. in Franklin, adding 9,000 square feet of laboratory space. The new building, which is scheduled to be operational in the summer of 2018, will allow B2S to grow its client base, which includes large contract research organizations (CROs), pharmaceutical companies, and smaller biotech businesses and startups. The company also plans to scale its reagent manufacturing to meet export demands and expand its services in biotherapeutic drug development.

B2S currently has 16 full-time employees and plans to begin hiring this year for scientists, project managers, statisticians, and business development and management associates. New positions are expected to offer average salaries above the state and county average wage. Interested applicants may learn more about the company’s career opportunities online or submit a resume at info@B2SLifeSciences.com.

“Recruiting and hiring local talent in the area is a priority for us,” said Dr. Ron Bowsher, chief scientific officer at B2S. “From the onset, we have worked together to enhance the local area where we live and work. This priority is reinforced by the fact that many of our lab staff reside in the southern portion of Marion County or Johnson County and by our close partnership with Franklin College. We look forward to continuing to grow the life sciences and biotech presence in central Indiana.”

Founded in 2015, the company specializes in drug development support with products and analytical services that facilitate drug research. Through its collaborative efforts, B2S scientists are contributing to advance treatments for cancer, diabetes and other chronic diseases. Along with its planned growth, the additional lab space will help propel biotech startups and other small operations. The company is also investing in central Indiana’s workforce by partnering with Franklin College to give Hoosier students the opportunity to receive hands-on experience through internships in applied biotechnology.

“Franklin is pleased to have B2S in our dynamic downtown. We look forward to seeing them expand and bring more economic diversity to our city,” said Franklin Mayor Steve Barnett.

The IEDC offered B2S up to $250,000 in conditional tax credits based on the company’s job creation plans. These tax credits are performance-based, meaning until Hoosiers are hired, the company is not eligible to claim incentives. This project was supported by the Johnson County Development Corporation and received grant funding and other tax incentives from the Franklin Development Corporation and Franklin Redevelopment Commission.

“This project gives B2S the opportunity to invest in highly skilled talent and jobs quicker than we would be able to achieve otherwise. Together, the state of Indiana, IEDC and city of Franklin have created an environment where small businesses can grow and prosper, allowing for quality of life improvements and business diversification in the region,” said Aleks Davis, chief executive officer at B2S.

Biotech companies like B2S are choosing to locate and grow their operations here because of Indiana’s reputation as a global leader in the life sciences industry. According to BioCrossroads and the Indiana Business Research Center, Indiana is the second largest exporter of life sciences products in the U.S. at $8.2 billion in total exports. More than 1,600 life science companies operate in the state, supporting more than 55,000 Hoosier jobs with average wages of nearly $95,000 annually.

About B2S Life Sciences
B2S Life Sciences LLC is a customer-focused biotherapeutic enablement company located in Franklin, Ind. The company sepecializes in bioanalytical consulting, immunoassay development, custom biological reagent generation and life-cycle management (LCM), immunogenicity cut point analysis, PK/TK statistics and advanced analytics. For more information about B2S, visit www.b2slifesciences.com.

About IEDC
The Indiana Economic Development Corporation (IEDC) leads the state of Indiana’s economic development efforts, helping businesses launch, grow and locate in the state. Governed by a 15-member board chaired by Governor Eric J. Holcomb, the IEDC manages many initiatives, including performance-based tax credits, workforce training grants, innovation and entrepreneurship resources, public infrastructure assistance, and talent attraction and retention efforts. For more information about the IEDC, visit www.iedc.in.gov
– 30 –
Media Contacts: 
Garrett Sheets (B2S Life Sciences) – 317.787.2213 or pr@B2SLifeSciences.com
Abby Gras (IEDC) – 317.232.8845 or agras@iedc.in.gov

Apexian Pharmaceuticals Opens Phase 1 Clinical Study of APX3330 in Patients with Solid Tumors

January 24, 2018

Apexian Logo Font

 

FOR IMMEDIATE RELEASE

Indianapolis, IN – January 24, 2018 – Apexian Pharmaceuticals, a clinical-stage biopharmaceutical company, has announced the opening of a clinical trial for patients with advanced solid tumors. The study involves APX3330, a first in class orally administered inhibitor of APE1/Ref 1, a dual-function protein that plays a critical role in promoting and maintaining a broad variety of cancers. Details of the study, including eligibility criteria, the location of participating clinical centers and referral contact information can be found at www.ClinicalTrials.gov, a website maintained by the National Institutes of Health.

 

The APE1/Ref-1 protein regulates the activity of other cancer-associated proteins, including transcription factors HIF-1-alpha, AP-1, NF-kappa B, and STAT3; proteins that control the aggressiveness of many cancers. Data indicates that Apexian’s drug APX3330 inhibits the cancer-promoting activity of APE1/Ref-1 without causing the side effects normally associated with many types of chemotherapy. Additionally, in a variety of pre-clinical studies APX3330 has been shown to not only have an anti-cancer effect, but to also prevent, and reverse the nerve damage caused by certain forms of chemotherapy.

 

The clinical study is the first to explore APX3330 use in patients with advanced cancer, and is the culmination of extensive research on APE1/Ref-1 and APX3330 conducted by Dr. Mark Kelley, Professor of Pediatrics and Associate Director of Basic Science Research at Indiana University’s Simon Cancer Center as well as other scientists worldwide. Dr. Kelley’s work on APE1/Ref-1 and APX3330 has previously resulted in significant research grants provided through the National Cancer Institute in order to explore APX3330’s potential to benefit cancer patients.

 

According to Dr. Richard Messmann, Apexian’s Chief Medical Officer, “Apexian’s research has provided us with a clear path to understanding, and an ability to measure, the clinical benefit that may be obtained when cancer patients are treated with APX3330. It also lays the foundation for determining whether patients with chemotherapy-induced peripheral neuropathy (CIPN) may benefit when receiving APX3330. The clinicians involved in the study, including those at the Simon Cancer Center and at START SA (San Antonio, TX) and START Midwest (Grand Rapids, MI) have uniformly expressed excitement regarding their participation in the study.”

 

“The initiation of the APX3330 study is a significant step forward in Apexian’s mission to develop safe and effective treatments for cancer patients,” said Steve Carchedi, President and CEO of Apexian Pharmaceuticals. “Despite recent advancements in cancer treatments, there continues to be a need for treatments that improve the survival of cancer patients. Apexian is committed to ‘moving mountains’ to help these patients.”

 

 

About Apexian Pharmaceuticals

Apexian Pharmaceutical’s mission is to develop safe and effective therapy for patients with high unmet medical needs.  Apexian’s lead drug candidate is APX3330, with additional promising agents in their drug-development pipeline. To learn more about Apexian Pharmaceuticals, please visit the company’s website at http://www.ApexianPharma.com

 

Media Contact:  Steve Carchedi

Email: PR@Apexianpharma.com, Telephone: 844-463-3330 x113

Former FDA regulatory scientist joins Pearl Pathways

January 20, 2018

PearlPathways

FOR IMMEDIATE RELEASE
Contact: Waylon Wright
Pearl Pathways
Business: (317) 602-5479
wwright@pearlpathways.com
http://www.pearlpathways.com

INDIANAPOLIS, INDIANA – January 18, 2018— Pearl Pathways announces the hiring of Robert Seevers, PhD as Senior Advisor to serve biopharmaceutical companies.

Seevers brings over 40 years of experience in pharmaceutical research and development for both large and small molecules. His expertise includes CMC regulatory, cold chain shipping, setting global specifications, quality by design (QbD), global regulatory submissions, and interactions with global regulatory agencies. His knowledge spans all major therapeutic areas with specific expertise in CNS, Endocrine, Metabolism, Autoimmune, Oncology, Radiopharmaceuticals, and drug delivery systems. Seevers’ robust clinical research experience includes acting as a primary investigator, Vice-Chair of an Institutional Review Board, FDA Reviewer/Team Leader, and medical writer.

Seevers’ career includes eight years at the United States Food and Drug Administration (FDA). At FDA, Seevers served as a Team Leader responsible for managing a team of reviewers for the evaluation of CMC sections of INDs, NDAs and BLAs. Prior to joining Pearl Pathways, Seevers spent 16 years with Eli Lilly and Company in Regulatory Affairs, where he led the regulatory CMC submission strategy for drugs in preclinical development through their NDA/MAA submission and the approval process for both small and large molecules.

As Senior Advisor at Pearl Pathways, Seevers is responsible for the development of the regulatory strategy for early through late stage regulatory filings of both large and small molecules, interactions with global regulatory agencies, leading cross-functional CMC development teams, helping clients identify product development vendors (e.g. CROs, CMOs, contract laboratories), and will serve on Pearl IRB, an AAHRPP accredited Independent Review Board.

Seevers is a member of the United States Pharmacopeia Packaging, Storing, and Distribution Expert Committee, acts as a Stability Consultant for the World Health Organization (WHO), speaks regularly at nation and international life science conferences, and continues to be an active writer of industry publications.

Diana Caldwell, President and CEO shares, “Our clients will benefit from Robert’s unique life science portfolio as an ex-FDA regulator coupled with extensive leadership experience within the biopharmaceutical industry. His dual-sided industry experience will be invaluable for our clients to navigate a variety of regulatory compliance challenges in both large multi-national companies and small startups. He brings expert technical knowledge of CMC development, drug substance synthetic processes, cold-chain shipping, radiopharmaceuticals, and global regulatory submissions including INDs, NDAs, and BLAs. We are thrilled to have Robert join our team.”

About Pearl Pathways
Pearl Pathways is a comprehensive life science product development services company. Every day we strive to provide our customers top quality service, unyielding ethics, and efficient services through our team of experts. Pearl Pathways supports biopharmaceutical, medical device, and diagnostic companies as well as life science service providers with clinical, regulatory, and quality compliance needs. Our AAHRPP accredited central IRB, Pearl IRB, supports all aspects of human research.
To learn more, please visit us at https://www.pearlpathways.com, call us at (317) 899-9341, or email contact@pearlpathways.com. Pearl Pathways is headquartered in Indianapolis, Indiana, with a regional office in Houston, Texas, and is AAHRPP accredited and a WBENC certified woman owned business.

For media inquiries, contact contact@pearlpathways.com

Apexian Pharmaceuticals is Closing a Series A Round to Initiate Phase 1 Trial

December 4, 2017

Apexian Logo Font

FOR IMMEDIATE RELEASE

Indianapolis, IN – November 29, 2017 – Apexian Pharmaceuticals, an Indiana-based clinical stage biotechnology company developing novel compounds to treat cancer, announced today that they are closing their Series A round. This financing follows previous investments as well as numerous grants and awards by the company since its founding. Proceeds will be used to initiate their phase 1 clinical study for APX3330 a novel first in class oral treatment for patients with cancer.

 

APX3330, the lead molecule for Apexian has a unique dual biological role targeting the APE1/Ref-1 protein.  The APE1 protein is a critical molecular “switch” controlling the activity of cancer regulatory proteins, including transcription factors HIF-1-alpha, STAT3, NF-kappa B, and AP-1. The Investigational New Drug application was issued based on robust non-clinical data and a safety database of over 422 patients in non-cancer studies. In addition, the data identified APE1/Ref-1 protein also plays a critical role in the repair of neuronal DNA that has been damaged through oxidative mechanisms which are common with platinum-containing chemotherapy agents. Apexian has developed robust non-clinical data demonstrating APX3330 prevents and/or reverses such damage and is the basis for pursuing an indication for Chemotherapy Induced Peripheral Neuropathy (CIPN).

 

Elevate Ventures, a venture development organization based in Indiana, committed funding through their Indiana 21st Century Research & Technology Fund, a direct investment vehicle overseen by the Indiana Economic Development Corporation positioned to support early-stage high-growth companies. “Apexian Pharmaceuticals has an impressive body of preclinical work in an exciting new target to treat cancer,” said Elevate Ventures Chief Executive Officer Chris LaMothe. “We look forward to joining other sophisticated investors to see this molecule tested in the clinical setting.”

 

Apexian Pharmaceuticals President and Chief Executive Officer Steve Carchedi commented: “We are very pleased to have an Indiana group, like Elevate Ventures join with others to enable this key data to be generated for our lead molecule. Developing a first-in-class oral molecule to treat pancreatic, colon and other difficult to treat cancers, is at the core of our mission. Cancer patients are truly waiting for novel treatments to attack these deadly diseases.”

 

About Elevate Ventures
Elevate Ventures nurtures and develops emerging and existing high-potential businesses into high-performing, Indiana-based companies. Elevate Ventures accomplishes this by providing access to capital, rigorous business analysis and robust advisory services that connect companies with the right mix of resources businesses need to succeed long-term. To learn more about its team and funds under management, visit www.elevateventures.com.

 

About Apexian Pharmaceuticals

Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs. Apexian’s lead drug candidate APX3330, is an oral first in class novel inhibitor of the APE1 protein, a critical node in cancer cell signaling. To learn more about Apexian Pharmaceuticals, please visit the company’s website at www.ApexianPharma.com

 

Media Contact:

Email: PR@Apexianpharma.com

Telephone: 844-463-3330 x113

Inscope Medical Solutions Launches First Laryngoscope with Integrated Suction

November 6, 2017

Available for demo at ACEP17, Inscope Direct cuts airway intubation time nearly in half when secretions are present

WASHINGTON–(BUSINESS WIRE)–Inscope Medical Solutions, an innovative medical device company, today announces the first laryngoscope with integrated, controllable suction. The Inscope Direct is a disposable laryngoscope that allows clinicians to maintain a clear view of the airway. Designed to be the best choice for trauma intubations, the device eliminates the need to juggle between yankauer suction and the endotracheal tube while securing the airway. The device is available for demo during the American College of Emergency Physicians Scientific Assembly (ACEP), at booth #2411, Oct. 29 – Nov. 1, 2017.

“Using the Inscope Direct is addicting. It’s easy to use and the controllable suction in the mouth throughout procedures keeps the right hand free to focus on passing the endotracheal tube”

Tweet this

Inscope Direct’s integrated suction removes secretions allowing a clear view of vocal cords for easy placement of the endotracheal tube. The device features a built-in LED light source and an anti-clog design with two controllable suction inlets eliminating the need for a yankauer suction catheter as it easily removes existing and re-accumulating secretions. Inscope Direct connects to standard suction tubing and is compatible with wall suction and powered portable suction. The convenient MAC 3.5 blade size fits most adults and each device is disposable to eliminate the risk of cross contamination.

“Using the Inscope Direct is addicting. It’s easy to use and the controllable suction in the mouth throughout procedures keeps the right hand free to focus on passing the endotracheal tube,” said Co-founder and Chief Medical Officer, Dr. Mary Nan Mallory. “Being able to easily suction while starting and throughout the intubation process is a game changer – it makes the first view a clear view, simplifying direct laryngoscopy every time.”

“Inscope Direct was born out of a real-life need following an incident where a founding physician had to treat a patient with life-threatening injuries, but struggled through the intubation process by juggling multiple pieces of equipment to clear the airway and pass the breathing tube. Every second is critical in emergency situations, and we knew there just had to be a better way,” said Co-founder and CEO Maggie Galloway. “We are thrilled to bring the Inscope Direct to market – not only for emergency intubations, but also planned intubations when secretions can unexpectedly become an issue. Now with the Inscope Direct, clinicians have at their disposal a tool that makes the intubation process more efficient and can improve outcomes for patients.”

In addition to the Inscope Direct, Inscope Medical plans to leverage its existing integrated suction technology in a forthcoming video laryngoscope.

To learn more, visit Inscope Medical Solutions at ACEP17 in booth 2411 in the main expo or at the Innovation Playground in innovateED for a hands-on demo. For more information on Inscope Direct visit www.inscopemedical.com.

About Inscope Medical Solutions

Inscope Medical Solutions is an innovative medical device company located in Jeffersonville, IN. Their first product, the Inscope Direct, is the first laryngoscope to integrate controllable suction to quickly remove secretions for a clear view of vocal cords allowing easy placement of the endotracheal tube. The company has won multiple awards for the Inscope Direct, including, JEMS 2017 Hot Product award at EMS Today Conference, Indiana Innovation Showcase winner, and a finalist for the 2017 Indiana Life Sciences Summit New Venture Competition. To learn more, please visit http://inscopemedical.com/ and follow us on LinkedIn, Twitter @inscopemedical, or Facebook.

Contacts

BLASTmedia for Inscope Medical Solutions
Emily Darr, 317-806-1900 ext. 121
emily@blastmedia.com

Singota Solutions announces partnership with Slope.io

October 19, 2017

Singota Solutions, a pharmaceutical contract development and manufacturing organization, expands service offerings through partnership with Slope.io, a clinical trial logistics automation service.

graphs on tablet shutterstock_105421988Bloomington, IN (October 18, 2017)–Singota Solutions announced its partnership with Slope.io to enhance outsourced management of clinical trial supplies. The partnership will benefit pharmaceutical firms in the clinical trial stage looking to streamline the tedious process of reordering and managing supplies.

Slope.io’s Clinical Trial Logistical Planning platform adapts, predicts, and responds to any clinical trial logistics scenario. The technology integrates directly into clinical trial data sources, reducing administrative burden to keep study sites provisioned with fresh supplies by utilizing automated supply ordering, resupply, and predictive forecasting.

Singota provides storage and materials management in its GMP warehouse that contains a range of storage conditions including 15-25°C, 2-8°C, -20°C, -80°C. Singota’s supply chain services include inventory management, expedited shipping services, and technical expertise in cold chain processes. In addition, Singota provides the pharmaceutical industry with state-of-the-art robotic aseptic manufacturing, formulation development, analytical testing, and labeling and kitting operations.

Singota’s ERP System is tightly integrated with Slope.io’s technology platform. Once needs are established with the trial specific replenishment algorithms created by Slope.io, Singota prepares materials and kits as necessary, and ships to trial sites as directed by Slope.io’s technologies. The combined expertise of Singota and Slope.io enables a breakthrough in clinical trial material operations proven to reduce delivery times, supply waste, and material costs, driving overall trial efficiency.

For more information, please contact Singota – info@singota.com or 812.961.1700.
About Singota Solutions
Singota Solutions is a service provider to the pharmaceutical, animal health, and medical device industries. Founded in 2006 as BioConvergence, the company is a woman-owned business operating in a 72,000-square foot facility in Bloomington, Indiana. The company’s service lines include aseptic manufacturing, supply chain operations, drug formulation development, analytical methods development & testing activities, and labeling & kitting operations. For more information, please visit www.singota.com.

About Slope.io
Slope.io is a clinical trial logistics automation service. The company uses a modern, data-driven technology platform with predictive analytics to enable patient-centered, automated, and end-to-end integrated services for clinical trial supplies. Trial data powers automated, just-in-time delivery of drugs and ancillary clinical supplies to study sites across the globe. For more information, please visit www.slope.io.

B-Start Selects 2017 Startups

October 18, 2017

FOR IMMEDIATE RELEASE

Media Contact:                                                                               

Anne McCombe

Project Manager, BEDC

(812) 335-7346

amccombe@bloomingtonedc.com

 

 

B-Start Selects 2017 Startups

Bloomington, IN (October 18, 2017) – B-Start, a pre-accelerator program for early-stage startups in Bloomington, announced its 2017 cohort today. Eleven startups were selected to participate in the 22-week program during which they will attend workshops in lean business concepts, customer acquisition, fundraising, marketing and more.

 

The program was opened to all Bloomington residents this year, including students from Indiana University and Ivy Tech Community College as in past years. B-Start has ushered 18 startups through the program since it was launched in 2015, with 7 still actively working on their businesses. In total, B-Starters have hired 5 new employees, and 3 have gone on to successfully participate in local business pitch competitions.

 

The newest group of B-Start participants focuses on a wide variety of industries. The eleven participants include:

  • Adventure Field Guides: Marketplace of trip guides made by a community of outdoor influencers
  • Be-u-tiful: Online marketplace that helps review and sell hair care products
  • Bot Maven: Software that creates bots for event promotions
  • Codemoji: Coding platform for kids using emojis
  • Community Carbon Exchange: Platform that facilities the financial exchange of personal carbon offsets between producers and consumers
  • Elephants on Mars: Virtual reality arcade to explore immersive VR and develop new technology
  • Eqlsr: Blockchain platform to share, curate, collaborate and listen to music
  • Nomad Chest: Platform for renting clothing to travelers
  • Rent My Window: Auction platform for brick-and-mortar businesses and advertisers
  • Sharon: Auction platform for brick-and-mortar businesses and advertisers
  • Thumb: Long-distance ride sharing platform for college students

 

“We are now in the third year of our B-start program, and are really excited to have non-students participating this year alongside students” said Anne McCombe, Project Manager of the BEDC. “Creating new businesses and plugging them in to the startup ecosystem in Bloomington is the goal of the B-Start program and this new cohort looks like one of our strongest yet.”

 

B-Start hosted a kickoff reception with the startups and business community on Wednesday, October 18th. Each of the B-Start participants will be paired with a local Bloomington entrepreneur who will serve as a mentor. The program culminates in a final Demo Day in March 2018 where the startups will deliver a 5-minute pitch with the chance to win cash prizes based on a panel of judges.

 

Founding sponsors for B-Start are Cook Group, Inc., Indiana University Office of the Vice President for Engagement, and The Gayle & Bill Cook Center for Entrepreneurship at Ivy Tech Community College Bloomington. For a full list of mentors, startups, and sponsors visit www.b-start.org.

 

About B-Start

B-Start is a pre-accelerator program of the Bloomington Economic Development Corporation (BEDC) to help launch for-profit innovation-driven businesses in Bloomington, Indiana. B-Start participants are at the earliest stage of their business development and are coached through a comprehensive process of cohort activities and individualized mentorship over the course of the program to build a foundation for acceleration. For more information, visit www.b-start.org.

 

About the BEDC

The BEDC is a not-for-profit organization dedicated to the retention, development and attraction of quality jobs in Monroe County. The BEDC is led by a partnership of private industry leaders, the City of Bloomington, Monroe County, Indiana University and Ivy Tech Community College–Bloomington. For more information, visit www.bloomingtonedc.com.

 

# # #

VisionTech Partners, Pearl Pathways Form Alliance to Fuel Growth in Indiana’s Life Sciences Startup Community

September 27, 2017

For Immediate Release

INDIANAPOLIS, Indiana (August 30, 2017) – – VisionTech Partners, the parent of Indiana’s most active angel investing group, and Pearl Pathways, a provider of life sciences product development services, have joined forces to fuel Indiana’s life sciences startup community, which includes biopharmaceutical, medical device and diagnostics technology.

 

The VisionTech Partners-Pearl Pathways alliance will focus on three essential goals. First, identify the most promising early stage/early growth companies for potential investment by VisionTech’s statewide network of angel investors. Second, connect entrepreneurs with individuals who have already achieved success in the life sciences and are willing to serve as mentors and business advisors. And finally, provide entrepreneurs with access to the highly specialized services required to negotiate the FDA approval process.

 

VisionTech Partners Executive Director Ben Pidgeon said both companies are eager to leverage their respective strengths through the alliance, which will formally launch Thursday, August 31, at VisionTech Angels’ “Pitch Night” in Indianapolis, featuring two life sciences startups.

 

“VisionTech Partners is extremely committed to growing Indiana’s life sciences industry and we’ve proven ourselves to be a valuable contributor to this effort as a source of financial and human capital. Of the 24 portfolio companies our angel network has invested in, 10 are in the life sciences and healthcare space; it’s definitely a sweet spot,” said Pidgeon.

 

“The alliance with Pearl Pathways will not only ensure a high quality deal flow, it will also help us make better investment decisions. Most of these companies must secure FDA approval in order to commercialize their drug, device or diagnostic tool. Pearl Pathways will, in effect, be VisionTech Partners’ resident expert on all things FDA,” he added.

 

Based in Indianapolis, Pearl Pathways is a life science product development services company that provides clinical research, regulatory, quality compliance, and independent review board services to life sciences companies. Among Pearl Pathways’ clientele are five of the top 20 medical device companies and six of the top 11 pharmaceutical companies in the world.

 

The balance of their business, said President and CEO Diana Caldwell, is startup companies with pre-commercialization technology that need access to early stage or “seed” funding provided by groups like VisionTech Partners.

 

“VisionTech Partners is unique in the angel investing space. Yes, they are a source of capital, but more importantly, they have deep experience and success in the life sciences industry. They also have a chapter composed entirely of physicians. These are the people who are around medical technology on a daily basis and have knowledge and insight few investors have. Partnering with VisionTech will not only open doors for our clients, startup companies across Indiana will benefit from the combined talents and resources of our two companies,” Caldwell said.

 

About VisionTech Partners I VisionTech Angels

Founded in 2008, VisionTech Partners is a privately held company focused on linking investors to high-potential early-stage companies. Headquartered in Indianapolis, among the nation’s most vibrant innovation regions, VisionTech is where inventors, entrepreneurs, investors, universities, and strategic partners convene to share, fund, and launch novel technologies. VisionTech Angels has chapters in Bloomington, Fort Wayne, Indianapolis, Lafayette, and an Affinity chapter, AngelBom.

 

About Pearl Pathways.

Founded in 2010, Pearl Pathways is a comprehensive life science product development consulting services company with expertise in regulatory, quality compliance, and clinical trial services including an AAHRPP accredited commercial IRB, Pearl IRB. Pearl Pathways works with clients’ clinical teams, in-house regulatory experts, the quality compliance specialists, quality auditors, and the senior leadership team to get life saving diagnostics and therapeutics on the market sooner.

Contact: Melanie Lux, mlux@luxandassociates.com, 803.331.4794

Contact: Waylon Wright, wwright@pearlpathways.com, 317.602.5479